survivin (baculoviral IAP repeat-containing protein 5) (21-28)

TFKNWPFL-acid

  • Description

  • Application Data

Description

Survivin is a member of the inhibitor of apoptosis (IAP) family; TFKNWPFL is the conserved part of the recognised cytotoxic T lymphocyte epitope.

See full description

Application Data

Catalogue number crb1001241
Molecular Weight 1051.5
Sequence (one letter code)

TFKNWPFL-acid

Sequence (three letter code)

H-Thr-Phe-Lys-Asn-Trp-Pro-Phe-Leu-OH

Purity >95%
Storage -20°C
References

Lladser et al., (2010). Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol. Immunother., 59:(1): 81. doi: 10.1007/s00262-009-0725-4.

Martini et al., (2016). Survivin is a guardian of the intestinal stem cell niche and its expression is regulated by TGF-β. Cell Cycle, 15(21):2875. doi: 10.1080/15384101.2016.1231286.

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Survivin is an intracellular tumour-associated antigen that is part of the inhibitor of apoptosis (IAP) family. Survivin expression increases as cells age but becomes over-expressed in cancer cells. Expression is also important during embryonic development and tissue regeneration. With roles in aging, apoptosis, and cancer, there is considerable interest in understanding the function of Survivin. Survivin expression is regulated by TGF-β and increased following intestinal inflammation during the healing process.

The high expression of Survivin in cancer cells has led to the search for a vaccine that induces epitope-specific CD8+ T cells. The epitope TFKNWPFL restricted to H-2 Db was identified using prediction algorithms and MHC class I binding assays. The epitope was delivered to mice by intradermal electroporation (EP). The Survivin epitope induced a  CD8+ cytotoxic T lymphocyte (CTL) response as shown by IFN-staining; they also showed an activated effector phenotype as CD44 and CD107 were upregulated. The Survivin vaccine was able to confer protection against melanoma in mice and suppress angiogenesis. This Survivin epitope could be a vital step in creating a human vaccine that generates CD8 CTLs with specific functional cytotoxic activity against tumour cells.

The sequence provided here aligns to residues 21-28 of the Survivin epitope, the initial residue of the epitope has been omitted as it is not conserved between mice and human sequences.

survivin (baculoviral IAP repeat-containing protein 5) (21-28)

Cat No.Pack SizePriceQty.
0.5mg£85.00
1mg£110.00
Bulk Quote